Back
Akero Therapeutics Vs. NovaBay Pharmaceuticals Industry Stock Comparison
Buy
73
AKRO
Akero Therapeutics
Last Price:
28.07
Seasonality Move:
-3.65%
Sell
43
NBY
NovaBay Pharmaceuticals
Last Price:
0.72
Seasonality Move:
-18.64%
Buy
73
Akero Therapeutics (AKRO)
is a Buy
Is Akero Therapeutics a Buy, Sell or Hold?
- The current Akero Therapeutics [AKRO] share price is $28.07. The Score for AKRO is 73, which is 46% above its historic median score of 50, and infers lower risk than normal.
- AKRO is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
43
NovaBay Pharmaceuticals (NBY)
is a Sell
Is NovaBay Pharmaceuticals a Buy, Sell or Hold?
- The current NovaBay Pharmaceuticals [NBY] share price is $0.74. The Score for NBY is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.
- NBY is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AKRO Stock Price Chart
What is Akero Therapeutics's stock price today?
-
The Akero Therapeutics share price today is $28.07
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and AKRO is experiencing buying pressure, which is a positive indicator for future bullish movement.
NBY Stock Price Chart
What is NovaBay Pharmaceuticals's stock price today?
-
The NovaBay Pharmaceuticals share price today is $0.74
The current trend is relatively stagnant and NBY is experiencing slight selling pressure.
AKRO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.45 | Buy |
| Relative Strength Index (14 RSI): | 62.09 | Buy |
| Chaikin Money Flow: | 623991 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (25.82 - 27.3) | Buy |
| Bollinger Bands (100): | (21.03 - 26.75) | Buy |
NBY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.06 | Sell |
| Relative Strength Index (14 RSI): | 61.79 | Buy |
| Chaikin Money Flow: | -53331864 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (0.45 - 0.57) | Buy |
| Bollinger Bands (100): | (0.56 - 3.36) | Sell |
AKRO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 26.89 | Buy |
| 20-day SMA: | 26.7 | Buy |
| 50-day SMA: | 26.3 | Buy |
| 200-day SMA: | 23.5 | Buy |
| 8-day EMA: | 27.15 | Buy |
| 20-day EMA: | 26.65 | Buy |
| 50-day EMA: | 25.83 | Buy |
| 200-day EMA: | 25.59 | Buy |
NBY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 0.52 | Buy |
| 20-day SMA: | 0.5 | Buy |
| 50-day SMA: | 0.83 | Sell |
| 200-day SMA: | 3.74 | Sell |
| 8-day EMA: | 0.55 | Buy |
| 20-day EMA: | 0.55 | Buy |
| 50-day EMA: | 0.94 | Sell |
| 200-day EMA: | 8.27 | Sell |
Akero Therapeutics Earnings Growth & AKRO Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.19 per share, a decrease next quarter of $0.18 per share, a decrease this year of $0.73 per share, and a decrease next year of $0.56 per share.
NovaBay Pharmaceuticals Earnings Growth & NBY Earnings Dates
- Analysts estimate an earnings increase this quarter of $13.87 per share, an increase next quarter of $0.05 per share, an increase this year of $78.20 per share, and an increase next year of $1.81 per share.
Akero Therapeutics Technical Analysis
| Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
NovaBay Pharmaceuticals Technical Analysis
| Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||